Cassady Schiller Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cassady Schiller Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$657	Buy	+2	New	+$679	﹤0.01%	895

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Cassady Schiller Wealth Management's BIO Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Bio-Rad Laboratories Class A (BIO) in Q4 2024: 2 shares worth $657. The stake represents ﹤0.01% of the portfolio and ranks #895 among its holdings.

456 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

Cassady Schiller Wealth Management held 2 shares of Bio-Rad Laboratories Class A worth $657 as of Q4 2024.
Bio-Rad Laboratories Class A was a new Cassady Schiller Wealth Management position in Q4 2024.
Bio-Rad Laboratories Class A made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #895 holding.
456 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.